Friday, March 20, 2020

08:15–08:30 Welcome

SESSION I – The genomic and epigenomic landscape of CLL and clinical consequences
Chairs: Jennifer Brown (Boston), Christopher Oakes (Columbus)

08:30-08:45 Genetic predisposition
Jennifer Brown (Boston)

08:45-08:50 Discussion

08:50-09:05 Genetic landscape
Cathy Wu (Boston)

09:05-09:10 Discussion

09:10-09:25 Ibrutinib
Jennifer Woyach (Colombus)

09:25-09:30 Discussion

09:30-09:45 Epigenetic landscape
Christopher Oakes (Columbus)

09:45-09:50 Discussion

09:50-10:05 Risk stratification in CLL: future perspective with focus on complex karyotype and NOTCH1 mutations
Panagiotis Baliakas (Uppsala)

10:05-10:10 Discussion

10:10-10:40 Panel discussion

10:40-11:10 Coffee Break

SESSION II – The role of BCR activation and signalling for CLL
Chairs: Paolo Ghia (Milan), Kostas Stamatopoulos (Thessaloniki)

11:10-11:25 BCR isotypes/autonomous signalling
Hassan Jumaa (Ulm)

11:25-11:30 Discussion

11:30-11:45 The latest news on stereotypes
Kostas Stamatopoulos (Thessaloniki)

11:45-11:50 Discussion

11:50-12:05 Novel BCR targets
Andrew Steele (Southampton)

12:05-12:10 Discussion

12:10-12:25 Next generation BTK inhibitors (covalent/non-covalent?)
Anthony Mato (New York)

12:25-12:30 Discussion
**SHORT ORAL COMMUNICATION**

12:30-12:37  *Mutational landscape of CLL mice models overexpressing aid identify proliferative-associated tumor genes involved in leukemic progression*  
Pablo Oppezzo (Montevideo)

12:37-12:40  *Discussion*

12:40-13:10  *Panel discussion*

13:10-14:50  *Lunch*

**13:30-14:30 SATELLITE SYMPOSIUM: Utilization of MRD assessment in the clinical management of CLL patients**

*Chair: Barbara Eichhorst (Cologne)*

*Speakers: Barbara Eichhorst (Cologne), Lanny Kirsch (Seattle), Anna Schuh (Oxford)*

*This symposium is organised and funded by Adaptive Biotechnologies.*

**SESSION III – Therapeutic options for CLL**

*Chairs: Alain Delmer (Reims), Michael Hallek (Cologne)*

14:50-15:05  Ibrutinib for everybody  
Jennifer Woyach (Columbus)

15:05-15:10  *Discussion*

15:10-15:25  Ibrutinib for a small subgroups only  
Florence Cymbalista (Bobigny)

15:25-15:30  *Discussion*

15:30-15:45  MURANO and MRD  
John Seymour (Melbourne)

15:45-15:50  *Discussion*

15:50-16:05  CLL14 update  
Kirsten Fischer (Cologne)

16:05-16:10  *Discussion*

**SHORT ORAL COMMUNICATION**

16:10-16:17  *Neddylation pathway regulates treg differentiation and T-cell function in Chronic Lymphocytic Leukemia ex vivo and murine in vivo studies*  
Scott Best (Portland)

16:17-16:20  *Discussion*

16:20-16:50  *Panel discussion*

16:50-17:20  *Coffee break*

**SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)**

*Chairs: George Follows (Cambridge), Jennifer Woyach (Columbus)*

17:20-17:35  Ibrutinib trials  
Alessandra Tedeschi (Milan)

17:35-17:40  *Discussion*
17:40-17:55 Ibrutinib real world  George Follows (Cambridge)
17:55-18:00 Discussion

18:00-18:15 Venetoclax trials  Matthew Davids (Boston)
18:15-18:20 Discussion

18:20-18:35 Venetoclax / PI3K real world  Anthony Mato (New York)
18:35-18:40 Discussion

SHORT ORAL COMMUNICATION

18:40-18:47 Sequential treatment with bendamustine, obinutuzumab (GA101) and ibrutinib in Chronic Lymphocytic Leukemia: final results of the CLL2-BIG trial of the German CLL study group (GCLLSG)  Julia von Tresckow (Cologne)
18:47-18:50 Discussion

18:50-19:20 Panel discussion

19:20 Get together and poster walks (stand up cocktails and buffet dinner for all)
- Biology poster walk: Alexey Danilov (Los Angeles), Davide Rossi (Bellinzona)
- Clinical poster walk: Matthew Davids (Boston), Alessandra Tedeschi (Milan)

Saturday, March 21, 2020

09:00-10:00 3 Simultaneous Meet the Expert sessions (non-clinical)

1. Prognostic and predictive markers  Barbara Eichhorst (Cologne)
2. Resistance to ibrutinib: what to do  Jennifer Brown (Boston)
3. First line therapy: continuous or time limited treatment?  Michael Hallek (Cologne)

10:00-10:30 Coffee break

SESSION V – The increasing role of the leukaemic microenvironment
Chairs: Alexey Danilov (Los Angeles), Adrian Wiestner (Bethesda)

10:30-10:45 Role of stromal cells  Andrea Brendolan (Milan)
10:45-10:50 Discussion

10:50-11:05 Hypoxia, metabolic reprogramming and immunosuppression occurring in CLL niche  Silvia Deaglio (Turin)
11:05-11:10 Discussion

11:10-11:25 Role of T cells  Arnon Kater (Amsterdam)
11:25-11:30 Discussion

11:30-11:45 Immunomodulatory effects of kinase inhibitors  Adrian Wiestner (Bethesda)
11:45-11:50 Discussion

SHORT ORAL COMMUNICATION

11:50-11:57 Expansion of antitumor cytotoxic CD8+ T cells in CLL patients treated with ibrutinib  Maria Joao Baptista (Badalona)
11:57-12:00 Discussion
12:00-12:30  Panel discussion

12:30-14:10  Lunch

SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL
Chairs: Matthew Davids (Boston), Peter Dreger (Heidelberg)

14:10-14:25  Next generation PI3K inhibitors
14:25-14:30  Discussion
Peter Hillmen (Leeds)

14:30-14:45  Novel inhibitors at preclinical level
(MCL1 & CDK inhibitors)
14:45-14:50  Discussion
Alexey Danilov (Los Angeles)

14:50-15:05  Mechanistic effects of BH3 Mimetics in CLL
15:05-15:10  Discussion
Eric Eldering (Amsterdam)

15:10-15:25  CAR-T cells
15:25-15:30  Discussion
David Maloney (Seattle)

15:30-15:45  Allo-transplant
15:45-15:50  Discussion
Peter Dreger (Heidelberg)

15:50-16:20  Panel discussion

16:20-16:50  Coffee break

SESSION VII – Efficacy through safety
Chairs: Barbara Eichhorst (Cologne), John Seymour (Melbourne)

16:50-17:05  Cardiologist
17:05-17:10  Discussion
Javid Moslehi (Nashville)

17:10-17:25  Dermatologist
17:25-17:30  Discussion
Nicole LeBoeuf (Boston)

17:30-17:45  Infectious diseases
17:45-17:50  Discussion
Pierluigi Viale (Bologna)

17:50-18:05  Gastroenterology
18:05-18:10  Discussion
Stefano Fagiuli (Bergamo)

18:10-18:40  Panel discussion

Free evening

Sunday, March 22, 2020

07:30-08:30  3 Simultaneous Breakfast Meet the Expert Sessions (clinical)

1.  Treatment of relapsed CLL
1.  Management of novel drugs side effect
2.  MRD assessment
   Paolo Ghia (Milan)
   Carol Moreno (Barcelona)
   Andrew Rawstron (Leeds)
SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance
Chairs: Davide Rossi (Bellinzona), John Seymour (Melbourne)

08:40-08:55  Clonal evolution  Davide Rossi (Bellinzona)
08:55-09:00  Discussion
09:00-09:15  PI3K  Jennifer Brown (Boston)
09:15-09:20  Discussion
09:20-09:35  Venetoclax  John Seymour (Melbourne)
09:35-09:40  Discussion

SHORT ORAL COMMUNICATIONS

09:40-09:47  Aid-mediated mechanisms of resistance to BCR inhibitors in Chronic Lymphocytic Leukemia (CLL)  Chiara Pighi (Turin)
09:47-09:50  Discussion
09:50-09:57  NOTCH2 contributes to venetoclax resistance in Chronic Lymphocytic Leukemia  Stefania Fiorcari (Modena)
09:57-10:00  Discussion
10:00-10:30  Panel discussion
10:30-11:00  Coffee break

SESSION IX – Contrasting therapeutic concepts:
Chairs: Jennifer Brown (Boston), Michael Hallek (Cologne)

11:00-11:15  MRD as a dynamic endpoint  Peter Hillmen (Leeds)
11:15-11:20  Discussion
11:20-11:35  Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction in lymphoid malignancies including CLL  David M. Kurtz (Stanford)
11:35-11:40  Discussion
11:40-11:55  Sequential vs combination treatments  William Wierda (Houston)
11:55-12:00  Discussion
12:00-12:15  Time limited vs continuous treatments  Barbara Eichhorst (Cologne)
12:15-12:20  Discussion
12:20-12:50  Panel discussion
12:50-13:00  Closing Remarks

MEETING CLOSURE